Objective:Photodynamic therapy (PDT) has become a well-established modality for the treatment of many cancers. Photodynamic eradication of tumor cells depends on the presence of a photosensitizer, oxygen and light. However, oxygen depletion during PDT is awell knownproblem. Modulation of light deliverycould address this issue bycounteractingtumor hypoxia, therebyimproving tumor cell killing. This preclinical studywas designed to validate an animal model incorporating 5-aminolaevulinic acid(5-ALA)-PDT usingU87 glioblastoma cells. We aimed to evaluate the effects of light modulation for inducing specific tumoral lesions in this model (i.e., necrosis or apoptosis).
Introduction
With an incidence of 3-5 cases/100,000 individuals/year, glioblastoma is the most common malignant primary tumor of the central nervous system 2 .The standard treatment isa combination of surgery, radiotherapy and chemotherapy, andit achieves a median patient survival time of 15months 37 . The goal of surgery is to achieve maximum tumor cytoreduction while preserving neurological function 42 . The majority of treatment failures are due to local recurrence of the tumor, suggesting that more aggressive local therapy could be beneficial 33 . Photodynamic therapy (PDT) is a local treatment based on light activation of a photosensitizer (PS) using a laser of aspecific wavelength 19, 32 . In the presence of oxygen, light interacts with the PS and formscytotoxic species. 5-Aminolevulinic acid (5-ALA) is a PS precursor. Indeed, the heme biosynthesis pathway leads to the production of 5-ALAinducedprotoporphyrin IX (PpIX), a endogenous PS 32 . PpIX is an excellent candidate for clinical PDT because of its highly selective uptake by tumors 23, 35, 39 . Furthermore, PpIX is relatively nontoxic, with a cutaneous photosensitization period limited to 1-2 days 35, 45 . These qualities are exploited during Fluoro-Guided Resection (FGR) of high-grade gliomas using 5-ALA.A randomized study demonstrated that complete resections of contrast-enhanced tumorswere more frequently achieved in malignant glioma patients when 5-ALA FGR was included 35 .
Previously, clinical studies reported promising results when employing PDT on patients suffering from recurrences of high-grade gliomas, with a median survival increase from 3-9months to 15months 4, 34 . Nevertheless, several issues still need to be addressed, including our ability toidentify the optimal doses of light and PS, the inter-individual variability in light distribution, and PS accumulation and tissue oxygenation. In particular, oxygen is a critical factor in the efficacy of PDT, as the cytotoxic effect of PDT is mediated by reactive oxygen species 17, 32 . Thus, in glioblastoma, pre-existing hypoxia is increased by the oxygen consumption required to carry out the photochemical reaction. This reversible tissue hypoxiamight significantly reduce the efficacy of PDT by decreasing the production of photochemical species 12, 17, 21 . Furthermore, the vasoconstriction of abnormal tumor microcirculation induced during PDT suppressesreperfusion andpotentially induces angiogenesis in the brain tissue adjacent to the tumor, subsequently contributing to tumor regrowth 49 .
Modulation of light delivery could decrease tissue hypoxia 10, 12 ,and low fluence rateshave beenreported to improve the efficiency of PDT, leading toincreasedapoptosis 3, 12, 27 . However, the delivery of such illumination schemes will likely require specific protocols or devices(e.g.,to repeatedly administer PS, an intracranial optical-fiber-based device might be necessary for several days).In addition, the application ofmultiple fractions of light exposure 12 at higher fluence ratesis being investigated as a means to counteract hypoxia.Fractions are defined as alternating 'on'/'off' periods that allow for reoxygenation Therefore, fractionation is expected to improve PDT because available molecular oxygencan be supplied by the capillary vasculature during the off-period.Fractionated PDT is promising because it may improve efficiency without dramatically increasing treatment time. Most studies on illuminationfractionation have investigated tumors in other locations, such as prostate cancers and skin lesions 15, 46 . Studies ofhigh-grade gliomas failed todemonstrate any benefit of fractionated illumination in PDT using HpD or m-THPC 9, 40 . These PSsappear to be less sensitive to fractionation, as they rapidly damaged tumor vasculature 8 . No experimental studies to date havereported the effects of fractionated 5-ALA-PDT on high-grade gliomas.
Based onpromising results inother areas of oncology, we investigated the effect of fractionated 5-ALA-PDT in a model of glioblastoma. Due to the importance of angiogenesis in glioblastoma, the most relevant modelinvolvesU87 gliomas engrafted into male fox1 rnu/rnu rat brains 38 . U87 is one of the most commonly used cell lines in the field of glioblastoma research 6, 18, 22, 25, 48 . This well-characterized cell line allows creates rapidly growing tumors with a high mitotic ratio and a satisfactory engraftment rate. Although U87 does not reproduce all the characteristics of human glioblastoma, such as spontaneous necrosis and an infiltrative pattern,these differences could be advantageous, as 1) the observed necrosis can be attributed completely to PDT, and 2) the absence of an infiltrative pattern should allow for more precise characterization of the treatment at a distance from the fiber tip.
Properly investigating the benefits of light fluence rates and of fractionation schemes requires a comprehensive experimental design including different groups of animals (e.g., high/low fluence rates, fractionation/no fractionation, andsham group with light/without light). Considering this, defining a preclinical model must be addressedbefore further studies can be performed. In this study, we define a proof of concept model as a basis for future studies. Thus, our main objective was to validate a preclinical model and experimental design for 5-ALA PDTwith respect to treatment response, grafting procedure, histology analysis and imaging procedures. Second, we studied the influence of light fractionation and light fluence rate using this model to define preliminary trendsfor the treatment response. Toward this end, two fluence rates and one light fractionation scheme were evaluated to prove the utility of the procedures and outline protocols for further study.
Materials and methods

Cell culture
PDT experiments were conducted using the U87 human glioma cell line (ATCC HBT-14). The cell line was cryopreserved in liquid nitrogen. U87 cells were grown as monolayers in DMEM (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), penicillin, streptomycin, Glutamax, pyruvate, and essential and nonessential amino acids. Cell culture plates were incubated at 37°C and 5% CO 2 . After harvesting the U87 cells with 0.25% trypsin, they were washed with Dulbecco's phosphatebuffered saline (PBS, Gibco Life Technologies) and counted.
Experimental animals
Athymic Fox1 rnu/rnu male rats (Harlan, Gannat, France) weighing 90-100 g (8 weeks old) at the start of the study were caged in air-filteredcages. The animal holding rooms were maintained at a constant temperature and humidity on a 12-hour light and dark schedule with an air exchange rate of 18 changes per hour. Animal care and protocols were in accordance with national legislation and institutional guidelines 16, 29 .The rats were anesthetized with isoflurane (1-2%) in oxygenduring tumor implantation, photo illumination and neuroimaging.
5-ALA preparation and administration
5-ALA was obtained as a hydrochloride powder. For intraperitoneal administration, 5-ALA was dissolved in PBS immediately before injection.All injections were intraperitoneal.
Rat glioma model
U87 glioblastoma cells (5 x 10 5 in 5 µl) were stereotactically implanted into the right putamenusing Paxinos atlas coordinates to induce intracerebral glioblastomas 31 . The anesthetized rats were fixed in a stereotactic frame (DavidKopf Instruments, Tujunga, CA, USA). The skin was incised under local anesthesia (lidocaine hydrochloride),and aburr hole was drilled at the following coordinates: 0.5mm anterior and 2.7mm to the right of the bregma. The needle was introduced through the burr hole and into the brain at a depth of 4.4mm, and 5 µl of culture medium was injected. A delay of 10min was observed between needle insertion into the brain and the onset of cell injection. The needle was left in place for 15min after completingthe injection to prevent the spread of tumor cells during retraction. The cells were injected at a rate of 0.5 µlmin -1 via an n o 30-G needle (RN G30 PST3 51 mm, Hamilton Company, Reno, NV, USA) fixed to a 10 µl microsyringe (1700 model 1701-RN, Hamilton Company) controlled by an electrical pump (KDS 310; KD Scientific, Holliston, MA, USA). Prior to needle introduction,an anchor 26 was erected to preserve a consistent position for grafting and treating. This anchor consisted of a cranial plate, a cannula projecting from the upper face of the plate and a prepositioning clip projecting from the bottom face of the plate. The cannula, the plate and the clip formed a hollow tube that guided the fiber perpendicular to the plate. The clip was positioned over the burr hole and then the anchor was positioned and fixed with biological tissue adhesive (Dermabond®, Johnson & Johnson/Ethicon, Somerville, NJ, USA). Finally, closure was performed around the cannula of the anchor using Vicryl 4/0 (Ethicon, Somerville, NJ, USA).
Magnetic resonance imaging (MRI)
After engraftment, U87 tumor-bearing rats were followed-up periodicallyusing a small-animal 7T MRI system (BrukerBioSpec, Ettlingen, Germany). Followinganesthesia, animals were subjected toT2-weighted (T2W) fast spin echo pulse sequences (TR=5000 ms, TE=77 ms, slice thickness=850 µm) and T1-weighted(T1W)fast spin echo pulse sequences (TR=400 ms, TE=9 ms, slice thickness=850 µm) with and withoutgadolinium (T1WGd)-basedcontrast (MultiHence,0.4 ml, i.p.). In the post-contrast studies, images were acquired 10 minutes after gadolinium administration. Tumor volumes were evaluated using standard viewing and reformatting software (OsiriX 4.1.2, 32-bit).The tumors were identifiedfrom their pathological contrast enhancement and the T2 signal. T2W sequences were alsolater used to assess perifocal edema. Tumor volume was computed by manual delineation based on each T2W image slice.The presence of an intratumoral hypointense signal was noted. MRI studies were performed at 7 and 14 days following engraftment and 48-72 hours after 5-ALA-PDT administration.
2.6.5-ALA-PDT of gross tumors
To determine the effects of 5-ALA-PDT on the tumors, 22 animals were subjected to treatment 14days following inoculation with U87 cells. In all cases, animals received i.p. injections of 100 mg/kg 5-ALA 36 ,and5-ALA-PDT was performed 5hours later. This time interval was chosen in accordance with previous experiments 30, 36 .Prior to illumination, animals were anesthetized and positioned in the stereotactic frame. A 350-µm, bare, flat-end quartz fiber with a 0.29 numerical aperture was introduced through the anchor and into the brain at a depth of 4.4 mm. The fiber was tightenedto the anchor, and the fiber was introduced into the tumor under the guidance of MRI.Light was delivered from a 635-nm diode laser. The animals were randomized into four treatment protocols. Animals in the continuous treatment modegroup were subjected to a radiant energy of 26 J at a radiant power of either 4.8mW (low-fluence-rate group, n=5) or 30mW (high-fluence-rate group, n=6). Forthe fractionated regime, rats were exposed to 26J at 4.8mW (n=5) or 26J at 30mW (n=6);in these two groups, the light dose was paused after 5 J for a duration of 120seconds before delivering the remaining light dose (21 J).The rats were euthanized 72 hours after 5-ALA-PDT and subjected to a final MRI. Their brainswere thenremoved and prepared forhistopathology.
2.7.Histological studies
The rodent brains were removed and fixed in formaldehydefollowingsacrifice(48-72 hours after PDT) or premature death. Brains were cut in thecoronal plane (along the tumor injection trace) and subjected to HES staining.Tumor necrosis was scored by a senior neuropathologist who was blinded to the treatment modalitiesbased on the number of HE-stained sections throughout the tumorsas none, sparse, or extensive. Macrophagic invasion and apoptotic reactions were also recordedin the sections.
Results
Across all of the experiments, a tumor engraftment rate of 82% was achieved.
Magnetic resonance imaging
A total of 22animals were treated using interstitial PDT (iPDT). Within two days oftreatment, 7 of the animals died ( Table 1 ).The remaining 15animals were investigated by MRI 48-72 hours after treatment. The tumors were observed on T2W as high-intensity signal areas at the sites of cell injection. No spread of tumor cells to other brain areas was detected. T2W images also revealededema in the brain adjacent to the tumor within a2 mm radius. No necrotic or cystic regions were observed in these tumors.
The median tumor volume was 1.9 mm 3 (0.35-5.1) on day 7and 10 mm 3 (0.84-55.2) on day 14following implantation. In particular, in terms of thefluence-rate groups, the median volume at 14 days was 15.8 mm 3 (1.44-55.2 mm 3 ) in thehigh-fluence-rate group and 4.2 mm 3 (0.84-11.9 mm 3 ) in the low-fluence-rate group. Following 5-ALA-PDT, the median tumor volume was 19.3 mm 3 (3.6-50.9 mm 3 ). For the post-treatment MRI, no significant changeswere visible using conventional sequences, including T2W and T1WGd images. Table 1 . Assignment of animals to various illumination groups.
3.2.Histology: variations in fluence rateandfractionation of light delivery
In total, 22 animals subjected to treatment were analyzed. Sevenanimalsfrom the highfluence-rate group died within 24 hours of treatment (4 in the fractionated group and 3inthecontinuous group). The remaining 15 animals were sacrificed following post-treatment MRI at 48-72 h. Representative sections from the treated tumors are presented in Fig. 1 , where the fiber tip path is shown(path estimated according to MRI slice, Fig. 1 (a) ) on the internal margin of the tumor.
Fig 1. Histological sections (a) Fiber path viewed by MRI.(b) Low-magnification (x10) microphotographs show sparse necrosis with an intact tumor;fiber path is indicatedwith a dashed arrow. (c) Extensive tumor necrosis. (d) High-magnification microphotographs (x20) showing the tumor border in a normal brain (B), necrosis (N), and an intact tumor core (T). (e) Necrosis and apoptotic bodies at higher magnification.
Thelevels of 5-ALA-PDT-induced necrosis in the HES-stained sections are shown in Table  2 .Necrosis was observedinboththe high-and low-fluence-rate groups. In most cases, the necrosis was sparse andlocalized around the fiber tip. Inthe high-fluence-rate group, increased necrosis was observed afterfractionated illuminationcompared with the continuous illumination group. Bycontrast, necrosis wassparse in the low-fluence-rate group even after fractionated treatment.
Table 2. Tumor necrosis in HE-stained sections after 5-ALA-PDT treatment with 26 J of light delivered at high or low fluence rates with fractionated or continuous illumination.
Macrophage infiltration and apoptotic reactions were also observed in the necrotic and intact tumor areas, and no 5-ALA-PDT-induced necrosis was detected in the normal brain. However, edema was observed in the brain tissue adjacent to the tumor, particularly after high-fluence rate illumination. 
Morbidity of interstitial PDT
Interstitial 5-ALA-PDT delivered at a high fluence rate 14 days after tumor induction resulted in clinical signs of elevated Intra Cranial Pressure (ICP) and wasfatal in 58% (7/12) of the animals in these groups. Over the course of our experiments, corticoids were used to counteract unexpected animal death when applying high fluence rates. Consequently, 4 of these 7 rats were not administered methylprednisolone following treatment. Therefore, the steroids were expectedto increase treatment tolerance.
All animals receiving 5-ALA-PDT at a low fluence rate survived the treatment and did not exhibit the severe symptoms of increased ICP after light exposure.
Theobserved post-treatment morbidity resulted froma combination of the 5-ALA-PDT response, the tumor volume and,most likely, hydrocephalus. Indeed, MRI images indicated several cases of hydrocephalus related to trapping of the ipsilateral horn of the lateral ventricle,which could have increased ICP. Two animals with hematomascaused by introduction of the optical fiber were also noted; one resulted in the death of the animal. Concerning the administration of 5-ALA, no adverse effect was observed.
Discussion
Based on our results, 5-ALA-induced PpIX appears to be a valuable PSbased on several criteria. First,good clinical tolerance was observed, 35 andprevious experimental and clinical studies demonstrated a high degree of selectivity in malignant glioma tissues 3, 23, 36, 41 The main factor limiting the efficacy of 5-ALA-PDT in the treatment of malignant glioma is tumor hypoxia, either pre-existing in the tumor or as a result of oxygen depletion during PDT. This hypoxia limits photochemical reactions that depend on oxygenand can consequently cause cellular destruction. Moreover, as a side effect, tumor hypoxia can induce angiogenesis and potentiate tumor regrowth.
In our study, we first aimed to validate a preclinical model and experimental protocol for 5-ALA PDT with respect to treatment response, grafting procedure, histology analysis and imaging procedures. These preliminary experiments enabled us to evaluate the effects of light modulation in this system. Indeed,previous studies suggested that the modulation of light delivery could enhance the efficiency of 5-ALA-PDT 3, 5, 20, 27 . For a given total light dose, low fluence rates were reported to be more effective compared with higher rates, 3,5,27 most likely because stronger and faster O 2 depletion wasassociated with higher fluence rates 12 . In our experiments, necrosis was observed at both low and high fluence rates. Nevertheless, the efficiency of the high fluence rate conflicted withprior results reported in the literature 3, 5, 30 .It is possible that the type of tumor used in our experiments could explain this discrepancy, asU87 tumorsare homogeneous, hypervascularized,and lack necrosis 7 . Furthermore, we observed alarge rangeof tumor volumes, which is a significant drawback of this investigation. In addition to randomizing the animals, this issue could have been avoided by waiting until MRI showed a minimum preset volume.In addition to necrosis, the neuropathologist also qualitativelyobserved macrophage infiltration and apoptotic reactions in the necrotic and intact tumor areas, although this observation requires quantitative investigation. Future studies involving specific apoptosis analyses should be performed using immunohistochemistry with the TUNEL method (Apoptag ® Plus Peroxidase In Situ, Millipore, USA).
The second part of our experimental work was designed to assess the enhanced efficacy of 5-ALA-PDT using light fractionation. The number of tumor-bearing animals available in this preliminary studywas limited, but the data strongly indicated that lightfractionation enhanced the effect of 5-ALA-PDT on tumor tissue. However, the effect of light fractionation was critically dependent on the treatment conditions.At the high fluence rate, our experiment revealed that the area of PDT necrosis increased when a single pause was introduced after delivering 5 J compared with continuous illumination. Although we did not find a similar difference at the low fluence rate, our results generally agreed with those of previous studies 11, 14, 15 ,whose authors postulated three processes to explain the efficacy of fractionated PDT. First, light exposure initially caused temporary vascular occlusion followed by hypoxia when the consumption of oxygen surpassesthe flow supplied by abnormal blood vessels. The dark period enabled reoxygenation of the tumor, making the subsequent light deliverymore efficient. The two other processes involve reperfusion injury and relocalization of the PS during the dark interval. Some studies have suggested that the effects are lessened when a low fluence rate is applied because the consumption of oxygen is slower 3, 5, 20 . Moreover, the benefits of fractionation was shown to be greater for 5-ALA than for certain other photosensitizers,based on its intracellular effect 14, 43 .PDT withmTHPC or Photofrin®(which exhibits a vascular effect)as the PS was not enhanced by fractionation of the light delivery 9, 40 .
In our study, we used a fractionation scheme described by Curnow et al. in the normal rat colon in which 5of the total 25J was delivered in the first fraction 14 . Curnow et al.demonstrated the importance of timingthe light delivery before the dark periodto avoid destroying the microcirculation necessary for further reoxygenation 13 . Another important feature ofthe dark period duration is thatthe O 2 recovery phase is likely to be tumor-type dependent owing to variations in vessel density, flow rate and oxygenation.It has therefore proven difficult thus far to define the optimal fractionation scheme. This change in oxygenation could potentially be monitored by measuringthe partial pressure of oxygen in the glioma and adjusting the duration of the on/off sequences 24 .
Clinical tolerancewas another factor affectingPDT efficiency. The observed post-treatment morbidity was likely due to increased ICP. These results suggested that a low fluence rate was better tolerated;however, it should be noted that, despite randomization, the average tumor volume in the high-fluence-rate group was higher than that in the low-fluence-rate group: 15.8 mm 3 (1.44-55.2) versus 4.2 mm 3 (0.84-11.9), respectively. Thus, PDT-induced edema contributed to the ICP and,in some cases, caused mortality when the tumor volume was high 4,28 .
This 5-ALA-PDT-induced edema is a common complication following PDT of brain tumors.It is typically addressed by administering steroids that improve clinical tolerance 3, 4, 28 . However, in our experiments, the effects of this adjuvant treatment were impaired when treating a high-volume tumor. Furthermore, tumor volume isknown to be a limiting factor during interstitial treatment 4 .
MRI is the most important tool for assessing the management of cerebral gliomas, although in our study,PDT efficacy was not properly evaluated usingT1W, T1WGd and T2W sequences. These results are not consistent with those reported by Beck et al. in a clinical study, which demonstrated a partial or complete resolution of tumorcontrast enhancement within 24 hours after 5-ALA-PDT 4 .Based on these preliminary experiments, we did not find any MRI evidence to corroborate our pathological findings. However, some groupshave reported the use of diffusion-weighted and perfusion MRIto evaluate the effects of vascular-targeted interstitial PDT 1, 44 .Therefore, the use of multiparametric MRI toassess PDT efficacy,without the need for histological examination,should be validated with comprehensive experimental designs, including low and high fluence rates, fractionation and continuous lighting assessed by sophisticated pathological analyses (e.g., apoptosis and necrosis). Finally, the dose of 100mg/kg used in this study was based on a former study by Stummer et al. 36 . The optimal dose has to be evaluated to optimize the PDT effects. A fluorescence microscopy study might be achieved for different doses to assess the optimal dose level.
Conclusion
In this study, we report the use ofinterstitial 5-ALA-PDT in a U87 glioblastoma rodent model. As angiogenesis is generally associated with glioblastoma, rats bearing U87 tumors rather than C6 tumors were chosen for these experiments 36, 47 .We established a reproducible and reliable rodent model for 5-ALA interstitial PDT. This new approach towardinvestigating 5-ALA-PDTallowed us to observe that its effect was critically dependent on the light delivery conditions. We therefore focused this study on assessing 1) the effects of interstitial PDT at high versus low fluence ratesof delivery and 2) the effect of fractionated light delivery. Our results suggest that fractionated PDT was more effective compared with continuous light delivery.Furthermore, we noted that the efficacy of fractionated delivery also depended on the rate of light delivery,with stronger effectsatthe high fluence rate. Indeed, fractionated light exposure at a radiant power of 30 mW induced more necrosis compared with that observed at 4.8 mW(either by fractionated or continuous PDT). However, low-fluence-rate 5-ALA-PDT was stillableto induce significant tumor necrosis.Finally, we show proof-of-concept experiments using the U87 glioblastoma rodent model to assess the effects of PDT. Future experiments should be performed to validate the effect of fluence rate and fractionation on pathology and to identify MRI markers forthese treatment effects. Toward this end, we are currently testing a significantly larger group ofanimals receiving 25 J at a rate of 30mW using two different fractionation schemes (compared with asham group) to evaluatemorbidity and side effects. Specific apoptosis analyses using immunohistochemistry with the TUNEL methodare also planned. 
